 |
|
 |
- December 1, 2008 |
|
|
Welcome to the #1 online source of information for Diabetes Specialists! An international online community of more than 10,000 Diabetes Specialists.
CME on Diabetes is a website built to transmit top-level CME conferences given by international experts in endocrinology, insulin resistance, prediabetes, metabolic syndrome and type 2 diabetes. More than 2.6 million slides have been viewed since the website launch. Thank you for your continued support and commitment!
|
|
|
| Presentation |
|
"PPAR effects linked to atherosclerosis independent of insulin sensitisation"Dr. Karin Jandeleit-Dahm (biography)
English - 2004-06-26 - 34 minutes
|
 | (37 slides) |
Summary :
In this presentation Dr. Jandeleit-Dahm describes the Peroxisome Proliferator-Activated Receptor (PPAR) isoforms and their distribution in different tissue types, and presents data from experimental studies focusing on the investigation of vascular and anti-atherosclerotic effects of thiazolidinediones, which are PPAR gamma agonists.
Previous animal studies have demonstrated anti-atherosclerotic effects of thiazolidinediones with an improvement in insulin resistance. The apolipoprotein E knockout (ApoE KO) mice - control and diabetic - have been used by Dr. Jandeleit-Dahm's group in order to study the vascular and anti-atherosclerotic effects of PPAR gamma ligands independently of their insulin-sensitising effects. Preliminary data suggest that rosiglitazone may have direct vascular and anti-atherosclerotic effects, and some effects of PPAR gamma ligand treatment were also observed in the kidneys of these mice.
ApoE KO mouse studies have also indicated an important role of the vascular renin-angiotensin system in the development and acceleration of diabetes-associated atherosclerosis.
Copyright © 2004 E-MedHosting.com Inc.
Learning objectives :
After viewing this presentation the participant will be able to discuss:
- The distribution and effects of PPAR isoforms
- Preliminary experimental data and proposed mechanisms for the direct vascular and anti-atherosclerotic effects of PPAR gamma ligands
- Evidence for a role of the renin-angiotensin system in the progression of diabetes-associated atherosclerosis
Bibliographic references :
O Braissant, F Foufelle, C Scotto, M Dauca and W Wahli. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat Endocrinology 1996; Vol 137, 354-366.
Riccardo Candido, MD; Terri J. Allen, PhD; Markus Lassila, PhD; Zemin Cao, MD; Vicki Thallas, BSc; Mark E. Cooper, MBBS, FRACP, PhD; Karin A. Jandeleit-Dahm, MD, PhD. Irbesartan but Not Amlodipine Suppresses Diabetes-Associated Atherosclerosis Circulation 2004; 109:1536-1542.
Riccardo Candido, MD; Karin A. Jandeleit-Dahm, MD, PhD; Zemin Cao, MD; Stefan P. Nesteroff;; Wendy C. Burns, BSc, (Hons), BEd; Stephen M. Twigg, MBBS, FRACP, PhD; Rodney J. Dilley, PhD; Mark E. Cooper, MBBS, FRACP, PhD; Terri J. Allen, PhD. Prevention of Accelerated Atherosclerosis by Angiotensin-Converting Enzyme Inhibition in Diabetic Apolipoprotein E–Deficient Mice Circulation. 2002;106:246
Chao-Hung Wang, MD; Nadia Ciliberti, BSc; Shu-Hong Li, MSc; Paul E. Szmitko, BSc; Richard D. Weisel, MD; Paul W.M. Fedak, MD; Mohammed Al-Omran, MD, MSc; Wen-Jin Cherng, MD; Ren-Ke Li, MD, PhD; William L. Stanford, PhD; Subodh Verma, MD, PhD. Rosiglitazone Facilitates Angiogenic Progenitor Cell Differentiation Toward Endothelial Lineage Circulation. 2004;109:1392-1400.
|
|
|
|
|
|
| Search our website |
 |
| |
Would you like to know more about insulin resistance? Are you looking for information pertaining to Type 2 Diabetes? You can find what you are looking for in over 2000 references available on CMEonDiabetes. |
| |
|
|
| Social |
|
| |
Let others know about this presentation.
|
|
|
|
